P-150 * RECURRENT TELOMERASE REVERSE TRANSCRIPTASE PROMOTER MUTATIONS IN NON-SMALL-CELL LUNG CANCERS
X. Ma,R. Wang,Y. Pan,H. Hu,H. Li,L. Wang,Y. Li,X. Luo,Y. Zhang,T. Ye,B. Li,D. Cai,Z. Sun,Y. Sun,H. Chen
DOI: https://doi.org/10.1093/icvts/ivu167.150
2014-01-01
Interactive Cardiovascular and Thoracic Surgery
Abstract:Objectives: Telomerase reverse transcriptase (TERT) is a ribonucleoprotein polymerase that maintains telomere ends. Mutations in TERT promoter could result in activation of telomerase complex and thus constitute a relevant mechanism for immortalization of cancer cells. Knowledge of the TERT promoter status may be of interest for molecular classification for non-small-cell lung cancer (NSCLC). We therefore analyzed the TERT promoter in 449 NSCLCs and identified their clinocapathologic characteristics. Methods: A total of 449 frozen surgically resected NSCLC tumour tissues were prospectively collected in the Department of Thoracic Surgery of Fudan University Shanghai Cancer Center. Clinical characteristics including age, sex, smoking status, stage, subtypes of lung adenocarcinoma, relapse-free survival (RFS) and overall survival (OS) were collected. TERT promoter were examined by RT-PCR and direct sequencing. Results: Of 449 tumours tested, 12 (2.67%) were found to harbour TERT promoter mutation, 4 with C228T, 2 with C250T, 2 with C216T, 1 each with C229G, C224T,G267C and C295T. Compared to the TERT mutation negative group, patients with TERT promoter mutation were significantly associated with older age (P = 0.042). Conclusions: TERT promoter mutations are recurrent mutated in 2.67% of NSCLCs and are highly enriched in older patients. TERT promoter mutations may play an important role in the pathogenesis of NSCLC and may serve a potential target for therapy. Disclosure: No significant relationships.